Evidence map›Paper›PMID 39225763›Full record

ArticleInternational urology and nephrology2025

A scoping review on adult patients with de novo glomerular diseases following COVID-19 infection or vaccine.

Liam Qi, Aman Deep, Jordan Fox, Mark Yii, Muhammad Rahman, Mar Myint, Htoo Myat, Zaw Thet

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Liam QiDepartment of Medicine, Prince Charles Hospital, Metro North Hospital and Health Service, Chermside, QLD, Australia.
Aman DeepDepartment of Nephrology, Central Queensland Hospital and Health Service, Rockhampton, QLD, Australia.
Jordan FoxThe University of Queensland Rural Clinical School, Rockhampton, QLD, Australia.
Mark YiiDepartment of Medicine, Flinders Medical Centre, South Adelaide Local Health Network, Bedford Park, SA, Australia.
Muhammad RahmanThe University of Queensland Rural Clinical School, Rockhampton, QLD, Australia.
Mar MyintK & K Kidney Health, Rockhampton, QLD, Australia.
Htoo MyatDepartment of Medicine, Canberra Hospital, Canberra Hospital and Health Service, Garran, ACT, Australia.
Zaw ThetDepartment of Nephrology, Central Queensland Hospital and Health Service, Rockhampton, QLD, Australia. zaw.thet@health.qld.gov.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are increasing reports of glomerular disease (GD) following COVID-19 infection and vaccination. Current evidence on the possible link between COVID-19 infection or vaccination and GD is conflicting.

objectiveThe present study undertakes a scoping review of research to describe the relationship between COVID-19 infection and vaccination with GD and the common management strategies and overall outcomes of the disease to identify knowledge gaps and guide further research. ELIGIBILITY CRITERIA: All original research studies published in English until 5th September 2022 were considered for inclusion in the review. Exclusion criteria were animal studies, autopsy studies, and data involving patients who were paediatric patients (< 16 years), were transplant recipients, had a recurrence of glomerular disease, had concomitant cancer or non-COVID-19 infection which may cause glomerular disease, or did not receive a renal biopsy. SOURCES OF EVIDENCE: The five electronic databases searched were MEDLINE, PubMed, Scopus, EMBASE, and Cochrane.

methodsTwo separate search strings related to COVID-19, and glomerular disease were combined using the Boolean operator 'AND'. Filters were used to limit publications to original research studies published in English. Search results from each database were imported into Covidence software ( www.covidence.org ) and used for de-duplication, article screening, and data extraction. Descriptive analyses were used to summarise demographics, diagnoses, and treatment outcomes.

resultsAfter removing duplicates, 6853 titles and abstracts were screened. Of the 188 studies included, 106 studies described 341 patients with GD following COVID-19 infection and 82 described 146 patients with GD following a COVID-19 vaccination. IgA nephropathy was the most common GD pathology reported following COVID-19 vaccination with GD most common following mRNA vaccines. Collapsing focal segmental glomerulosclerosis was the most common GD following COVID-19 infection. Immunosuppressive treatment of GD was more common in the vaccine cohort than in the infection cohort.

conclusionDespite the significant number of COVID-19 infections and vaccinations around the world, our understanding of GD associated with COVID-19 infection and vaccination remains poor, and more research is needed to understand the possible relationship better.

Indexed as

COVID-19COVID-19 VaccinesGlomerulonephritisAdultHumansSARS-CoV-2COVID-19 VaccinesCOVID-19 infectionCOVID-19 vaccinationGlomerular diseaseGlomerulonephritisGlomerulopathy

Identifiers

PMID39225763
PMCPMC11772384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.